OrthoPediatrics Sees FY24 Revenue $200M-$203M Vs $198.125M Estimate
$KIDS
Medical/Dental Instruments
Health Care
OrthoPediatrics Sees FY24 Revenue $200M-$203M Vs $198.125M Estimate
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/25/2024 | $39.00 → $31.00 | Buy → Hold | Truist |
| 3/3/2022 | $83.00 → $65.00 | Buy | Needham |
| 12/22/2021 | $75.00 → $68.00 | Buy | BTIG |
| 12/21/2021 | $78.00 → $75.00 | Buy | Truist Securities |
| 8/6/2021 | $70.00 → $77.00 | Market Outperform | JMP Securities |
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
Truist Securities analyst Samuel Brodovsky maintains OrthoPediatrics (NASDAQ:KIDS) with a Hold and lowers the price target from $38 to $35.
Truist Securities analyst Samuel Brodovsky maintains OrthoPediatrics (NASDAQ:KIDS) with a Hold and raises the price target from $35 to $38.
7 analysts have expressed a variety of opinions on OrthoPediatrics (NASDAQ:KIDS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for OrthoPediatrics, presenting an average target of $40.29, a high estimate of $50.00, and a low estimate of $32.00. Witnessing a positi
WARSAW, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at two upcoming investor conferences being held in New York, NY. Event:Stifel 2024 Healthcare ConferenceFormat:Fireside ChatDate:Tuesday, November 19, 2024Time:10:55 am ET Event:Piper Sandler 36th Annual Healthcare ConferenceFormat:Fireside ChatDate:Tuesday, December 3, 2024Time:9:00 am ET An audio webcast of the discussion will be available online at the OrthoPediatrics' inv
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
Truist downgraded OrthoPediatrics from Buy to Hold and set a new price target of $31.00 from $39.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $65.00 from $83.00 previously
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Business Highlights Helped a record 32,000 children in the second quarter of 2024, an increase of 52% from the second quarter 2023Generated record total revenue of $52.8 million for the second quarter of 2024, up 33% from $39.6 million in second quarter 2023; domestic revenue increased 39% and international revenue increased 16% in the quarterGrew worldwide Trauma & Deformity
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
10-Q - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the "Alliance for Pediatric Device Innovation" (APDI), to advice the development and commercialization of medical devices designed for children. Along with Children's National, APDI consortium members include Johns Hopkins University, CIMIT at Mass General Brigham, Tufts Medical Center and Medstar Health Research Institute. The Company will serve as APDI's strategic advisor and role model for devic
New CEO Paul Mraz also joins FzioMed Inc.'s Board of Directors; Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, Calif., Jan. 3, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors. Mraz's appointment became effective Jan. 1, 2023, commensurate with the retirement of John Krelle who served in the leadership role since 2005. "On behalf of the Board of Directors, I want to thank John for
WARSAW, Ind., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022. Mark Throdahl, Executive Chairman of OrthoPediatrics' board said, "We are pleased to have attracted an Operations executive of Jimmy's stature to our company, which has an extensive supplier network of outsourced products. Beyond his directly relevant experience, Jimmy brings a wonderful personal fit with the culture of our board and our company." Mr. McDonald currently is Vice Pr